Mr. Thau is co-chair of Morrison & Foerster’s 140-lawyer Life Sciences Group. His practice focuses on the representation of life science, medical device, and other technology companies at all stages of their life cycles, from company formation, equity and debt financing, merger and acquisition transactions, strategic alliances and public offerings. He also represents venture capital and investment banking firms in public and private financing transactions. He has represented companies and investors in over a hundred venture capital and debt financing transactions, as well as in numerous public offerings and public and private M&A transactions.

Mr. Thau’s clients include AcelRx Pharmaceuticals, Allux Medical, Altair Therapeutics, Baxano, Catalyst Biosciences, DURECT Corporation, Horizon Therapeutics, Osteologix, SurModics and Visiogen. Mr. Thau also represents venture capital firms including CHL Medical Partners, CMEA Ventures, Prospect Venture Partners, Three Arch Partners and Thomas, McNerney & Partners and has represented underwriters including AG Edwards & Sons, Inc. and CS First Boston.